Pfizer launches 20-valent Pneumococcal Conjugate Vaccine for adults in India

12 Aug 2025 Evaluate

Pfizer has launched its next-generation 20-valent pneumococcal conjugate vaccine (PCV20) for adults in India. With broader serotype coverage, Pfizer’s vaccine marks a significant advancement in protection against pneumococcal disease in adults. Pfizer’s vaccine helps protect against clinically relevant 20 serotypes responsible for a majority of invasive and non-invasive pneumococcal disease.

It enables timely and proactive protection for all adults, including those living with chronic conditions. PCV20 will be available as a single shot vaccine and those vaccinated with PCV20 may not need a second dose. Adults over 50 years of age, as well as individuals with comorbidities such as asthma, COPD (Chronic Obstructive Pulmonary Disease), chronic kidney disease, and diabetes, face a higher risk of developing pneumococcal infections, which can result in complications, hospitalization, and even death.

Timely immunization is critical to reducing the risk of severe illness, hospitalization, and mortality caused by pneumococcal disease. Vaccination with PCVs are considered one of the most effective public health tools for reducing the burden of pneumococcal disease. The introduction of PCV20 in India strengthens Pfizer’s longstanding commitment to preventive health and builds on 25 years of leadership in pneumococcal vaccine innovation.

Pfizer is engaged in manufacturing, marketing, trading and export of pharmaceutical products.


Pfizer Share Price

4995.25 -7.55 (-0.15%)
05-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×